Trial
NCT03736967
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Regeneron Pharmaceuticals
Collaborators
Sanofi
Condition
Atopic Dermatitis
Intervention
REGN3500
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-01